Compare Cognizant Technology Solutions Corp (CTSH) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cognizant Technology Solutions Corp vs BIO-TECHNE Corp — how do they compare? Cognizant Technology Solutions Corp trades at $60.2 (market cap $27.03B), while BIO-TECHNE Corp trades at $72.46 (market cap $11.36B). The key difference: Cognizant Technology Solutions Corp is far larger — about 2.4× BIO-TECHNE Corp's market cap, and Cognizant Technology Solutions Corp pays the higher dividend (2.2%). Which is the better fit depends on your goals — on Pluang, investors hold Cognizant Technology Solutions Corp for 57 Days and BIO-TECHNE Corp for 63 Days on average.
| CTSH | TECH | |
|---|---|---|
Market Cap | $27.03B | $11.36B |
Volume | 9,883,888 | 5,390,331 |
Sector | Technology | Health |
52-Week High | $86.70 | $72.61 |
52-Week Low | $38.73 | $43.31 |
Typical Hold Time | 57 Days | 63 Days |
Enterprise Value | $28.08B | $11.39B |
Dividend Yield | 2.2% | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cognizant Technology Solutions (CTSH) trades at $57.07, down 0.26% with bearish technical signals despite recent earnings beats. The stock shows attractive valuation metrics with P/E of 12.25 and EV/EBITDA of 6.52, while maintaining solid profitability with 10.26% net margin. Recent news highlights the company's AI transformation initiatives and recognition as a top employer, though Q2 2026 earnings missed expectations.
CTSH presents a compelling value opportunity with strong fundamentals and analyst consensus target of $64.25 (12.6% upside). Risks include IT spending pressures from AI disruption and competitive threats. The upcoming Q3 2026 earnings report on October 29, 2026 will be critical for validating the company's growth trajectory amid industry headwinds.
TECH trades at $72.53, near its 52-week high of $72.70, with a bullish technical signal from moving averages. The company reported mixed quarterly earnings, beating in Q4 2025 and Q2 2026 but missing in Q1 2026. Revenue for 2025 was $1.22B, with a net income margin of 14.97%. Valuation ratios are elevated, with a P/E of 62.46 and P/S of 9.36. A significant development is the shareholder-approved acquisition by Merck KGaA at $73.00 per share, pending completion.
The outlook is heavily influenced by the pending acquisition, offering a near-term price ceiling. Fundamentals show solid profitability but high valuation multiples. Risks include acquisition deal completion uncertainty and integration challenges. Analyst sentiment is mixed with no sell ratings, but the consensus price target of $65.78 suggests limited upside from current levels, making the stock a hold pending acquisition closure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cognizant Technology Solutions Corp
Cognizant is a global IT services provider, offering consulting and outsourcing services to some of the world's largest enterprises spanning the financial services, media and communications, healthcare, natural resources, and consumer products industries. Cognizant employs nearly 300,000 people globally, roughly 70% of whom are in India, although the company's headquarters are in Teaneck, New Jersey.
Read more on CTSH →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
